Organon Reports Q1 2023 Revenue Growth, Highlights Women’s Health and Biosimilars Progress
Organon (NYSE: OGN) has released its financial report for the first quarter of 2023, announcing...
Finanical Reports
EQRx Inc. Abandons Plans for Low-Cost Drugs, Terminates Development of Three China-Sourced Products
US-based biotech EQRx Inc., (Nasdaq: EQRX) has disclosed in its Q4 2022 financial report a...
Mindray Reports Strong YOY Growth in 2022 and Q1 2023 Financial Results
China-based medical device firm Mindray (SHE: 300760) has released its financial reports for the year...
BeiGene Reports Q1 2023 Financial Growth, Advances Pipeline with Global Expansion Plans
China-based BeiGene, Ltd. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has reported financial results for the...
Q1 2023 financial report: AstraZeneca leads innovation in China, Sanofi’s sales in China decline
Several multinational companies (MNCs) have released their Q1 2023 financials, showing a varied performance over...
CSPC Pharmaceutical Group Reports 11% YOY Revenue Growth in 2022 Financial Results
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has released its 2022 financial report, recording RMB...
Roche’s Q1 2023 Report: 3% Dip in Revenues with Strong Growth in Pharmaceuticals
Roche (SWX: ROG), the Swiss pharmaceutical and diagnostics giant, reported a 3% year-on-year (YOY) decrease...
GSK Reports Q1 2023 Revenue Dip Amid COVID-19 Treatment Decline, Underlying Growth
UK-based multinational GlaxoSmithKline plc (GSK, NYSE: GSK) has released its financial results for the first...
MicroPort Scientific Corp. Reports 8% Revenue Growth and Increased R&D Investment in 2022
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has released its 2022 annual financial...
WuXi AppTec Reports 5.77% YOY Revenue Growth and 31.97% Increase in Net Profits for 2023Q1
WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for the...
YiChang HEC ChangJiang Pharmaceutical Reports 309.83% YOY Revenue Growth in 2022 Financials
YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558), a China-based pharmaceutical company, has released its...
Lee’s Pharmaceutical Holdings Ltd Reports 2022 Revenues and Pipeline Updates
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its 2022 financial report, recording HKD...
Jiangsu Hengrui Pharmaceuticals Reports 2022 Revenue Dip and Increased R&D Investment
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a China-based pharmaceutical company, has released its 2022 financial report,...
CanSino Biologics Reports 2022 Revenue Drop and Increased Losses Amid COVID-19 Vaccine Market Shifts
China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has released its 2022 financial report, recording...
Simcere Pharmaceutical Group Reports 26.4% YOY Revenue Growth in 2022 Financials
Simcere Pharmaceutical Group (HKG: 2096), a China-based pharmaceutical company, has reported its financial results for...
Henlius Reports 97.2% YOY Revenue Growth in Q1 2023, Highlighted by Strong Sales of Hanquyou and HaiSiZhuang
China-based biopharmaceutical company Henlius (HKG: 2696) has released its financial report for the first quarter...
Huadong Medicine Reports 9.12% YOY Revenue Growth and 13.24% Increase in Net Profits for 2022
Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has released its 2022...
Henlius Reports 91.1% Revenue Growth in 2022, Driven by Product Commercialization
China-based Henlius (HKG: 2696) has announced its annual results for 2022, revealing that revenues reached...
Everest Medicines Reports 2022 Revenue Growth and Pipeline Updates
China-based Everest Medicines (HKG: 1952) has released its financial report for 2022, along with key...
Harbour BioMed Reports 846.5% YOY Revenue Increase and Expands R&D in 2022 Financials
Global biotechnology company Harbour BioMed (HKG: 2142), with operations in the United States, the Netherlands,...